Answers are grounded in this paper and cite their sources.
Clinical applications of PARP inhibitors in metastatic prostate cancer show promise, suggesting improved outcomes when chemotherapy is not indicated.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Oudard et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: